Ethyl 2,4,6-trihydroxybenzoate is an agonistic ligand for liver X receptor that induces cholesterol efflux from macrophages without affecting lipid accumulation in HepG2 cells

Bioorganic & Medicinal Chemistry Letters
2012.0

Abstract

The present study reports a novel liver X receptor (LXR) activator, ethyl 2,4,6-trihydroxybenzoate (ETB), isolated from Celtis biondii. Using a reporter gene assay, time-resolved fluorescence resonance energy transfer (TR-FRET), and surface plasmon resonance (SPR) analysis, we showed that ETB directly bound to and stimulated the transcriptional activity of LXR-α and LXR-β. In macrophages, hepatocytes, and intestinal cells, ETB suppressed cellular cholesterol accumulation in a dose-dependent manner and induced the transcriptional activation of LXR-α/-β-responsive genes. Notably, ETB did not induce lipogenic gene expression or cellular triglyceride accumulation in hepatocytes. These results suggest that ETB is a dual-LXR modulator that regulates the expression of key genes in cholesterol homeostasis in multiple cells without inducing lipid accumulation in HepG2 cells.

Knowledge Graph

Similar Paper

Ethyl 2,4,6-trihydroxybenzoate is an agonistic ligand for liver X receptor that induces cholesterol efflux from macrophages without affecting lipid accumulation in HepG2 cells
Bioorganic & Medicinal Chemistry Letters 2012.0
The discovery of tertiary-amine LXR agonists with potent cholesterol efflux activity in macrophages
Bioorganic & Medicinal Chemistry Letters 2009.0
N-Acylthiadiazolines, a New Class of Liver X Receptor Agonists with Selectivity for LXRβ
Journal of Medicinal Chemistry 2007.0
Discovery and structure-guided optimization of tert-butyl 6-(phenoxymethyl)-3-(trifluoromethyl)benzoates as liver X receptor agonists
Bioorganic & Medicinal Chemistry Letters 2015.0
Discovery of tissue selective liver X receptor agonists for the treatment of atherosclerosis without causing hepatic lipogenesis
European Journal of Medicinal Chemistry 2019.0
Discovery of tetrahydro-cyclopenta[b]indole as selective LXRs modulator
Bioorganic & Medicinal Chemistry Letters 2009.0
Indazole-Based Liver X Receptor (LXR) Modulators with Maintained Atherosclerotic Lesion Reduction Activity but Diminished Stimulation of Hepatic Triglyceride Synthesis
Journal of Medicinal Chemistry 2008.0
DrugBank screening revealed alitretinoin and bexarotene as liver X receptor modulators
Bioorganic & Medicinal Chemistry Letters 2017.0
1-(3-Aryloxyaryl)benzimidazole sulfones are liver X receptor agonists
Bioorganic & Medicinal Chemistry Letters 2010.0
Design, synthesis and pharmacology of 1,1-bistrifluoromethylcarbinol derivatives as liver X receptor β-selective agonists
Bioorganic & Medicinal Chemistry Letters 2015.0